Back to search results

Health Benefits of Writing Therapy for Asian American Cancer Survivors

This study is looking at how writing about your experiences with cancer might help your health. If you are an adult (18 or older) Asian American who has been diagnosed with stage 0-III cancer (or certain types of leukemia), you might be able to join. Participants will write essays about their cancer journey in English or Chinese and answer questionnaires over about a year. Researchers want to see if writing therapy can improve your quality of life and reduce stress. They will also look at how writing might affect stress biomarkers (things in your body that show stress). The study aims to understand the benefits of writing therapy for Asian American cancer survivors.

Study design
This is an interventional study planning to enroll 180 participants. It is not specified if it's randomized or blinded.
What's involved
You will write essays once a week for 3 weeks at the start, and then one more time 9 months later. You will also answer questionnaires at the beginning, and then 3, 6, and 12 months later.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for an average of 1 year, with questionnaires at 3, 6, and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06367959

Health Benefits of Writing Therapy Among Asian American Cancer Survivors

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~180 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:EsaysQuestionnaires

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Outcome Measure: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Measured over Time Frame: through study completion; an average of 1 year

Conditions

Cancer

Explore related trials

Acute LeukemiaBreast CarcinomaChronic Myeloid Leukemia, BCR-ABL1 PositiveHematologic NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Qian Lu, MD, PHD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult (aged 18 and older) diagnosed with stage 0-III cancer (or acute leukemia in remission/ chronic myeloid leukemia in chronic phase).
Self-identified as Asian, Asian Americans, any Asian or Asian American subgroup (Chinese, Vietnamese, Indian, Korean, etc.) ethnic/cultural background
Completed primary treatment, including surgery, chemotherapy, and/or radiation therapy, immunotherapy, or targeted therapy within the preceding 5 years.
Comfortable reading in English or in Chinese.

What this trial measures

  • Primary Outcome Measure: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Time Frame: through study completion; an average of 1 year